Easton Pharmaceuticals Inc (OTCMKTS:EAPH) has been moving up steadily on accelerating volume in recent days after the Company announced COFEPRIS (Mexican Ministry of Health) has granted Marketing Authorization for VagiSan (also known as VS-Sense) diagnostic test, supporting on-going exclusive partnership negotiations for Mexico and other Latin American markets.
EAPH has been around for years and was initially formed as L.A.M. Pharmaceutical, Corp on July 24, 1998. After a 3000 for 1 reverse stock split in 2009 the Company changed their name from LAM Industries Inc., to Easton Pharmaceuticals Inc.
Easton Pharmaceuticals Inc (OTCMKTS:EAPH) was a specialty pharmaceutical company involved in various pharmaceutical that joined the pot boom in 2013. The Company previously owned an FDA approved wound healing drug and currently owns topically-delivered drugs and therapeutic cosmetic healthcare products focused on cancer and other health issues geared towards female sexual dysfunction, wound healing, pain, motion sickness and other conditions that are all in various stages of development.
EAPH ventured into the potentially lucrative medical marijuana industry through an investment into AMFIL Technologies and their groZONE anti-bacterial system and the exclusive option to purchase up to 49% in a medical marijuana grow-op business / facility which has received a letter to build from Health Canada. The company’s gel formulation is thought to be an innovative and unique transdermal delivery system that can in the future be adaptable in the delivery of Cannabidiol extracts.
EAPH might be a good place to be if pot stocks heat up and there is plenty to suggest they will including Canada’s new prime minister promising legalization immediately, DEA being told by California judge to stop interfering with dispensaries, billionaire Richard Branson suggesting a decriminalization amendment in the U.N., 6,000 non-violent drug offenders released Nov 1st, Australia lifting ban on medical MJ, New York opening medical MJ dispensaries January, Colorado revenues increasing etc.
To Find out the inside Scoop on EAPH Subscribe to Microcapdaily.com Right Now by entering your Email in the box below
On October 7 EAPH updated shareholders on a number of issues; In March of this year, Easton Pharmaceuticals entered into a 50/50 profit-sharing partnership agreement with a partner whereby both companies currently possess exclusive distribution rights for the country of Mexico and the rest of Spanish speaking Latin America from Israel-based Common Sense Ltd. and their patented product lines known as VS-SENSE-OTC and VS-SENSE PRO, for the detection of Bacterial Vaginosis (BV) and Trichomonas and AL-SENSE Amniotic Fluid Leak Detection Test.
EAPH recently retained the services of Dr. Jose Tiran, a Thought Leader in women’s health. Dr. Jose Tiran and Easton Pharmaceuticals believe the endeavor with BMV for the distribution rights within Mexico and Central and South America for the patented woman’s diagnostic products from Common Sense Ltd., will be approved and able to deliver consistent, growing sales for Easton Pharmaceuticals commencing within the next 3 to 6 months.
Easton/BMV will initially launch in Mexico through medical sales reps and offer four products: the VS-Sense Vaginal Discharge diagnostic plus two treatment options: a European-approved natural lactic acid gel for when the diagnosis suggests Bacterial Vaginosis, and a terconazol-based yeast infection treatment for when the diagnostic suggests yeast infection. This is a similar triangle model Bayer HealthCare AG who has the exclusive European rights has recently launched in Europe.
On September 26 EAPH announced COFEPRIS (Mexican Ministry of Health) has granted Marketing Authorization for VagiSan (also known as VS-Sense) diagnostic test, supporting on-going exclusive partnership negotiations for Mexico and other Latin American markets with several multinational pharmaceutical companies.
The filing, review and approval process has taken over a year which is longer than originally anticipated, but a remarkably short period of time given the average time to approval is between two and three years for most Health Sector products in Mexico. The approval is in Ackerman Pharma’s name, fulfilling the legal requirement that the Marketing Authorization holder have an Establishment License. This is common practice in Mexico where the “host” holds the approval in the name of the sponsor company.
We have a Monster Pick Coming. Subscribe Right Now!
Currently trading at a $2.7 million market valuation EAPH has minimal assets or revenues and manageable debt. But EAPH is an exciting story developing in small caps; the Company has been putting out some big press since entering the red hot Cannabis sector and from a technical standpoint the stock trades just a hair over 52 week lows of $0.0056 and it has a long history of highly explosive moves like the sub pennies to dime run in 2014. We will be updating on EAPH when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with EAPH.
Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!
Disclosure: we hold no position in EAPH either long or short and we have not been compensated for this article.